Literature DB >> 25467015

Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis.

L Barrera1, E Montes-Servín2, A Barrera3, L A Ramírez-Tirado4, F Salinas-Parra2, J L Bañales-Méndez5, M Sandoval-Ríos6, Ó Arrieta7.   

Abstract

BACKGROUND: Immunoregulatory cytokines may play a fundamental role in tumor growth and metastases. Their effects are mediated through complex regulatory networks. Human cytokine profiles could define patient subgroups and represent new potential biomarkers. The aim of this study was to associate a cytokine profile obtained through data mining with the clinical characteristics of patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: We conducted a prospective study of the plasma levels of 14 immunoregulatory cytokines by ELISA and a cytometric bead array assay in 110 NSCLC patients before chemotherapy and 25 control subjects. Cytokine levels and data-mining profiles were associated with clinical, quality of life and pathological outcomes.
RESULTS: NSCLC patients had higher levels of interleukin (IL)-6, IL-8, IL-12p70, IL-17a and interferon (IFN)-γ, and lower levels of IL-33 and IL-29 compared with controls. The pro-inflammatory cytokines IL-1b, IL-6 and IL-8 were associated with lower hemoglobin levels, worse functional performance status (Eastern Cooperative Oncology Group, ECOG), fatigue and hyporexia. The anti-inflammatory cytokines IL-4, IL-10 and IL-33 were associated with anorexia and lower body mass index. We identified three clusters of patients according to data-mining analysis with different overall survival (OS; 25.4, 16.8 and 5.09 months, respectively, P = 0.0012). Multivariate analysis showed that ECOG performance status and data-mining clusters were significantly associated with OS (RR 3.59, [95% CI 1.9-6.7], P < 0.001 and 2.2, [1.2-3.8], P = 0.005).
CONCLUSION: Our results provide evidence that complex cytokine networks may be used to identify patient subgroups with different prognoses in advanced NSCLC. These cytokines may represent potential biomarkers, particularly in the immunotherapy era in cancer research.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  biomarkers; cytokines; data-mining analysis; non-small-cell lung cancer; prognosis

Mesh:

Substances:

Year:  2014        PMID: 25467015     DOI: 10.1093/annonc/mdu549

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  31 in total

1.  Interplay between immune cells in lung cancer: beyond T lymphocytes.

Authors:  Juan-Manuel Hernandez-Martinez; Edgar Vergara; Edgar Montes-Servín; Oscar Arrieta
Journal:  Transl Lung Cancer Res       Date:  2018-12

2.  IL-33 Signaling in Lung Injury.

Authors:  Jing Chang; Yue-Feng Xia; Ma-Zhong Zhang; Li-Ming Zhang
Journal:  Transl Perioper Pain Med       Date:  2016

3.  Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer.

Authors:  Chan-Young Ock; Ah-Rong Nam; Ju-Hee Bang; Tae-Yong Kim; Kyung-Hun Lee; Sae-Won Han; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang; Do-Youn Oh
Journal:  Gastric Cancer       Date:  2015-12-17       Impact factor: 7.370

Review 4.  IL-33 in Tumor Immunity: Nothing to Sneeze At.

Authors:  Donye Dominguez; Yi Zhang; Bin Zhang
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

5.  IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.

Authors:  Mauricio S Caetano; Huiyuan Zhang; Amber M Cumpian; Lei Gong; Nese Unver; Edwin J Ostrin; Soudabeh Daliri; Seon Hee Chang; Cesar E Ochoa; Samir Hanash; Carmen Behrens; Ignacio I Wistuba; Cinthya Sternberg; Humam Kadara; Carlos Gil Ferreira; Stephanie S Watowich; Seyed Javad Moghaddam
Journal:  Cancer Res       Date:  2016-04-01       Impact factor: 12.701

6.  Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer.

Authors:  Kayhan Erturk; Didem Tastekin; Murat Serilmez; Elif Bilgin; Hamza Ugur Bozbey; Sezai Vatansever
Journal:  Tumour Biol       Date:  2015-07-29

Review 7.  Biomarker development in the precision medicine era: lung cancer as a case study.

Authors:  Ashley J Vargas; Curtis C Harris
Journal:  Nat Rev Cancer       Date:  2016-07-08       Impact factor: 60.716

8.  Plasma secretome analyses identify IL-8 and nitrites as predictors of poor prognosis in nasopharyngeal carcinoma patients.

Authors:  Ahmed Amine Zergoun; Kyle S Draleau; Faycal Chettibi; Chafia Touil-Boukoffa; Djamel Djennaoui; Taha Merghoub; Mehdi Bourouba
Journal:  Cytokine       Date:  2022-03-09       Impact factor: 3.926

Review 9.  Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer.

Authors:  Mario Orozco-Morales; Giovanny Soca-Chafre; Pedro Barrios-Bernal; Norma Hernández-Pedro; Oscar Arrieta
Journal:  Mediators Inflamm       Date:  2016-01-28       Impact factor: 4.711

10.  An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer.

Authors:  Charlotte O'Donnell; Amr Mahmoud; Jonathan Keane; Carola Murphy; Declan White; Sinead Carey; Micheal O'Riordain; Michael W Bennett; Elizabeth Brint; Aileen Houston
Journal:  Br J Cancer       Date:  2015-12-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.